

# Biliary Tract Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight

*Biliary Tract Cancer Market Forecast-2034 report offers an in-depth understanding of the forecasted epidemiology as well as the market trends in the 7MM.*

LAS VEGAS, NV, UNITED STATES,  
December 19, 2024 /  
EINPresswire.com/ --

DelveInsight's "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Biliary Tract Cancer Market Forecast](#)

Some of the key facts of the Biliary Tract Cancer Market Report:

- The Biliary Tract Cancer market size is anticipated to grow with a significant CAGR during the study period (2020–2034)
- In November 2024, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL injection for intravenous use to treat adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as identified by an FDA-approved test. Ziihera received accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months, as assessed by independent central review (ICR). Continued approval may depend on confirmation of clinical benefit in a follow-up trial. The Phase 3 HERIZON-BTC-302 trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy compared to standard-of-care therapy alone in the first-line treatment of HER2-positive BTC.
- In August 2024, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical

company focused on oncology and developing proprietary antibody-based therapeutics for various diseases, today announced the completion of patient enrollment in its COMPANION-002 trial. The trial, a randomized Phase 2/3 study, involves 150 patients and evaluates CTX-009 in individuals with biliary tract cancer (BTC).

- In June 2024, Bold Therapeutics, a global leader in the development of innovative metallothiopyridone-based therapeutics, announced positive Phase 2 safety and efficacy results for its lead asset, BOLD-100, in the treatment of advanced metastatic biliary tract cancer (BTC) and gastric cancer (GC) at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
- The overall number of BTC incident cases in the 7MM population in 2022 was found to be 38,000. Japan was the country with the highest number of cases of BTC cancer, followed by the US.
- Of the total number of stage-specific BTC cases in EU4 and the UK in 2022, around 89% were of Stage IV, compared to approximately 18% in Japan and approximately 37% in the US
- A total of approximately 16,000 BTC patients were treated in the US in 2022; 4,500 of these cases were localized and regional, 8,000 were first-line advanced or metastatic cases, and 3,000 were second-line and above advanced or metastatic cases.
- In Japan, around 45% of BTC patients were 80 years of age or older in 2022. In the US, about 24% of BTC patients were 80 years of age or older, and about 29% of patients were between the ages of 70 and 79.
- Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
- Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
- The Biliary Tract Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tract Cancer pipeline products will significantly revolutionize the Biliary Tract Cancer market dynamics.

### Biliary Tract Cancer Overview

Biliary Tract Cancer (BTC) is a rare and aggressive cancer that originates in the bile ducts, which are responsible for carrying bile from the liver to the small intestine. It includes cancers of the bile ducts inside and outside the liver, as well as the gallbladder. Symptoms can be vague and may include jaundice, abdominal pain, and weight loss, often leading to delayed diagnosis. BTC is typically diagnosed in later stages, making treatment more challenging. Treatment options may include surgery, chemotherapy, and targeted therapies, depending on the cancer's location and stage.

Get a Free sample for the Biliary Tract Cancer Market Report:

[https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=gpr](https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr)

### Biliary Tract Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

### Biliary Tract Cancer Epidemiology Segmentation:

The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Prevalence of Biliary Tract Cancer
- Prevalent Cases of Biliary Tract Cancer by severity
- Gender-specific Prevalence of Biliary Tract Cancer
- Diagnosed Cases of Episodic and Chronic Biliary Tract Cancer

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ [Biliary Tract Cancer Epidemiology Forecast](#)

### Biliary Tract Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancer market or expected to get launched during the study period. The analysis covers Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Biliary Tract Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

### Biliary Tract Cancer Therapies and Key Companies

- Keytruda (pembrolizumab): Merck Sharp & Dohme
- Imfinzi (durvalumab): AstraZeneca
- Futibatinib (TAS-120): Taiho Oncology
- Melphalan: Delcath Systems
- E7090 (tasurgratinib): Eisai

- TT-00420: TransThera Sciences (Nanjing)
- ARQ 087 (Derazantinib): Basilea Pharmaceutica
- Lenvima (lenvatinib): Eisai and Merck & Co
- Zanidatamab: Zymeworks and BeiGene
- XmAb20717: Xencor, Inc.
- Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
- CTX-009: Compass Therapeutics
- MEDI5752: AstraZeneca
- Brigimadlin: Boehringer Ingelheim
- ZB131: ZielBio, Inc.
- GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
- BNT141: BioNTech SE
- SO-C101: SOTIO Biotech
- CT-0508: Carisma Therapeutics Inc
- RAIN-32: Rain Oncology Inc
- AVA6000: Avacta Life Sciences Ltd
- DB-1303: DualityBio Inc.

#### Biliary Tract Cancer Market Strengths

- The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.

#### Biliary Tract Cancer Market Opportunities

- Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.

#### Scope of the Biliary Tract Cancer Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
- Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others

- Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
- Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Biliary Tract Cancer Unmet Needs, KOL's views, Analyst's views, Biliary Tract Cancer Market Access and Reimbursement

To know more about Biliary Tract Cancer companies working in the treatment market, visit @ [Biliary Tract Cancer Clinical Trials and Therapeutic Assessment](#)

## Table of Contents

1. Biliary Tract Cancer Market Report Introduction
2. Executive Summary for Biliary Tract Cancer
3. SWOT analysis of Biliary Tract Cancer
4. Biliary Tract Cancer Patient Share (%) Overview at a Glance
5. Biliary Tract Cancer Market Overview at a Glance
6. Biliary Tract Cancer Disease Background and Overview
7. Biliary Tract Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Biliary Tract Cancer
9. Biliary Tract Cancer Current Treatment and Medical Practices
10. Biliary Tract Cancer Unmet Needs
11. Biliary Tract Cancer Emerging Therapies
12. Biliary Tract Cancer Market Outlook
13. Country-Wise Biliary Tract Cancer Market Analysis (2020–2034)
14. Biliary Tract Cancer Market Access and Reimbursement of Therapies
15. Biliary Tract Cancer Market Drivers
16. Biliary Tract Cancer Market Barriers
17. Biliary Tract Cancer Appendix
18. Biliary Tract Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

## About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/770353900>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.